Business · 25.09.2026

Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments

The Food and Drug Administration (FDA, the Agency, or we) is hosting a hybrid public meeting to discuss proposed recommendations for the reauthorization of the Biosimilar User Fee Act (BsUFA) for fiscal years (FYs) 20…